Vetter strikes out on new pathways to further develop the injection process.
CDMO launches the Vetter Open Innovation Challenge under the slogan Injection 2.0
Swiss pharma giant Novartis announced that its monoclonal antibody for migraine prevention Aimovig (erenumab) has received market approval in the EU. It is the first treatment of its kind to be available here.
Spanish Capital Cell continues to be a pioneer in the health crowdfunding scene and launched a new self-funding fundraising round to create the first ICO marketplace for health via Blockchain.
A financing agreement with the European Investment Bank will allow the French cancer specialist Nanobiotix to borrow up to €40m through loan – money the company needs to boost its research, development and innovation activities.
Morphosys has named Jennifer Herron President of MorphoSys US Inc. to build up sales presence overseas.
The EU Court of Justice has ruled that plants created using novel genome editing methods will be classed as genetically modified organisms and therefore have to follow the strict EU guidelines for GMOs.
Irish Nabriva Therapeutics plc has acquired San Diego-based antibiotics developer Zavante Therapeutics for 8.2 million shares plus US$97.5m in milestone payments.
US gene editing expert Sangamo Therapeutics is set to acquire French biotech TxCell in an all-cash buyout of €72m on a debt- and cash-free basis.
Analysts say Roches bispecific antibody Hemlibra will rock the US$15bn haemophilia A market, given that it may circumvent therapy resistance that affects the 30% of patients who form antibodies against recombinant factor VIII products. European Biotechnology spoke with Dr. Gallia Levy, Associate Group Medical Director at Roche, who led clinical development of Hemlibra.
Swedish Orphan Biovitrum AB (Sobi) has signed a €387 deal with Swiss drug developer Novimmune for a late stage antibody targeting a rare haematology disorder.